Genscript Biotech Corporation
GNNSF | OTC
$4.50
$0.00 (0.00%)
At close: Oct 28, 2026, 9:30 AM ET
$4.50
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 5:00 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 403.25M | 440.75M | 518.77M | 309.33M | 285.16M | 448.22M | 391.31M | 316.11M | 309.59M | 260.53M | 229.57M |
Cost of Revenue | 197.03M | 208.18M | 198.14M | 170.71M | 151.66M | 213.71M | 216.26M | 180.52M | 141.09M | 116.63M | 90.95M |
Gross Profit | 206.21M | 232.57M | 320.63M | 138.62M | 133.51M | 234.51M | 175.05M | 135.59M | 168.5M | 143.9M | 138.62M |
Operating Income | 49.43M | 76.15M | 179.09M | 331K | 8.95M | -193.22M | -222.57M | -260.74M | -177.23M | -226.96M | -152.32M |
Interest Income | 7.9M | 16.22M | 711K | 28.89M | 100.55M | 32.22M | 13.45M | 3.18M | 1.07M | 5.32M | 1.14M |
Pretax Income | -119.13M | -470.41M | -119K | -42.87M | -127.93M | -106.33M | -244.65M | -201.91M | -229.78M | -367.14M | -150.22M |
Net Income | -129.03M | -507.37M | -25.46M | 3.14B | -175.12M | -1.9M | -93.58M | -91.34M | -135.51M | -267.59M | -91.12M |
Selling & General & Admin | 117.43M | 116.51M | 110.22M | 109.41M | 99.65M | 202.23M | 190.29M | 183.84M | 168.13M | 187.59M | 115.81M |
Research & Development | 39.35M | 39.91M | 31.32M | 28.88M | 24.91M | 225.5M | 207.33M | 212.49M | 177.61M | 183.27M | 175.13M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 156.78M | 156.42M | 141.54M | 138.29M | 124.55M | 427.73M | 397.62M | 336.38M | 399.34M | 516.35M | 287.7M |
Interest Expense | 6.38M | 8.11M | n/a | 8.03M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 51.98M | 47.51M | 45.07M | 43.05M | 92.89M | 81.4M | 81.41M | 86.94M | 109.7M | 58.27M |
Cost & Expenses | 353.81M | 364.6M | 339.68M | 309M | 276.21M | 641.44M | 613.88M | 516.9M | 540.43M | 632.98M | 378.65M |
Income Tax Expense | 9.9M | 37.44M | 24.43M | 6.84M | 9.81M | 3.04M | 1.1M | -7.53M | 3.81M | -4.96M | 5.93M |
Shares Outstanding (Basic) | 2.19B | 2.18B | 1.18B | 2.18B | 2.12B | 1.99B | 2.11B | 2.1B | 2.09B | 2.08B | 1.98B |
Shares Outstanding (Diluted) | 2.19B | 2.23B | 2.16B | 2.18B | 2.12B | 2.11B | 2.11B | 2.1B | 2.09B | 2.09B | 1.98B |
EPS (Basic) | -0.06 | -0.24 | -0.01 | 0.01 | -0.05 | 0 | -0.04 | -0.04 | -0.06 | -0.13 | -0.05 |
EPS (Diluted) | -0.06 | -0.23 | -0.02 | 0.01 | -0.05 | 0 | -0.04 | -0.04 | -0.06 | -0.13 | -0.05 |
EBITDA | 89.76M | 108.68M | 208.93M | 28.25M | 41.79M | -164.28M | -194.24M | -236.13M | -152.77M | -209.45M | -132.12M |
EBIT | 49.43M | 76.15M | 179.09M | 331K | 8.95M | -193.22M | -222.57M | -260.74M | -177.23M | -226.96M | -152.32M |
Depreciation & Amortization | 40.32M | 32.53M | 29.84M | 27.92M | 32.84M | 28.94M | 28.33M | 24.61M | 24.47M | 17.51M | 20.21M |
Add to Watchlist
Select watchlists to add or remove GNNSF